Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...

The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

Leqembi (lecanemab-irmb) is a prescription drug that treats Alzheimer’s disease by removing certain proteins to reduce plaques in your brain. Your response to this drug may vary based on your ...

The presented trial results, especially in MCI patients, are promising, particularly as Alzheon is targeting a subset of ...

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous ...

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...

The European Medicines Agency committee declined to approve Eli Lilly's Alzheimer’s treatment, citing risks of brain bleeding ...

Like Leqembi, Kisunla is designed to clear sticky clumps of a protein called amyloid beta, believed to be a hallmark of Alzheimer's, from the brain. Lilly has expanded its direct-to-consumer ...